<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794699</url>
  </required_header>
  <id_info>
    <org_study_id>IDE397-001</org_study_id>
    <nct_id>NCT04794699</nct_id>
  </id_info>
  <brief_title>Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion</brief_title>
  <official_title>An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEAYA Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEAYA Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, multicenter, multiple dose, dose escalation study of the&#xD;
      safety, PK, PD, and anti-tumor activity of IDE397 as a single agent in adult patients with&#xD;
      selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to&#xD;
      standard of care therapy or for whom no curative therapy is available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicities (DLTs) of IDE397</measure>
    <time_frame>21 days following the first dose of IDE397</time_frame>
    <description>Incidence of DLTs of IDE397 will be determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>MTD and RP2D of IDE397 will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of IDE397 and metabolite</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Pharmacokinetics of IDE397 and metabolite following single and multiple oral administration will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Objective response rate and duration of response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect of IDE397</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Changes in the levels of MAT2A pathway (SAM and MAT2A) and PRMT5 pathway (SDMA) will be determined</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE397 dosed orally, once daily (QD) for each 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDE397</intervention_name>
    <description>Small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A)</description>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be at least 18 years of age&#xD;
&#xD;
          -  Advanced or metastatic solid tumor that has progressed on at least one prior line of&#xD;
             treatment or is intolerant to additional effective standard therapy&#xD;
&#xD;
          -  Have evidence of homozygous loss of MTAP or MTAP deletion at the DNA or protein level&#xD;
             in the participant's tumor tissue&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  ECOG performance status &lt;= 1 or 2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Able to swallow and retain orally administered study treatment&#xD;
&#xD;
          -  Able to comply with contraceptive/barrier requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known symptomatic brain metastases that are not neurologically stable for 3 months&#xD;
&#xD;
          -  Known primary CNS malignancy&#xD;
&#xD;
          -  Current active liver or biliary disease&#xD;
&#xD;
          -  Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular&#xD;
             disease or previous gastric resection or lap band surgery&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of IDE397&#xD;
&#xD;
          -  Active, uncontrolled infection including hepatitis B virus, hepatitis C virus, human&#xD;
             immunodeficiency virus, or acquired immunodeficiency syndrome related illness&#xD;
&#xD;
          -  Baseline 12 lead ECG that demonstrates clinically relevant abnormalities&#xD;
&#xD;
          -  Clinically significant cardiac events 6 months before study entry&#xD;
&#xD;
          -  Uncontrolled hypertension despite optimal medical therapy&#xD;
&#xD;
          -  Previous treatment with a MAT2A inhibitor and / or PRMT inhibitor&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to C1D1&#xD;
&#xD;
          -  Radiation therapy within 4 weeks prior to C1D1&#xD;
&#xD;
          -  Systemic anti-cancer therapy (non-monoclonal antibody) within 4 weeks prior to study&#xD;
             entry or within 28 days prior to study entry for an antibody based agent(s) or 5&#xD;
             half-lives (whichever is shorter)&#xD;
&#xD;
          -  Have received radioimmunotherapy less than 6 weeks before the first dose of IDE397&#xD;
&#xD;
          -  Have received treatment with a therapeutic antibody less than 4 weeks before the first&#xD;
             dose of IDE397&#xD;
&#xD;
          -  Have received treatment with an investigational small molecule less than 2 weeks&#xD;
             before the first dose of IDE397&#xD;
&#xD;
          -  Prior irradiation to &gt;25% of the bone marrow&#xD;
&#xD;
          -  Current use or anticipated need for food or drugs that are known strong CYP3A4/5&#xD;
             inhibitors&#xD;
&#xD;
          -  Current use or anticipated need for food or drugs that are known strong CYP3A4/5&#xD;
             inducers&#xD;
&#xD;
          -  Received an investigational product within 28 days prior to first dose of IDE-397 or 5&#xD;
             half-lives (whichever is shorter)&#xD;
&#xD;
          -  Exposure to more than 4 investigational medicinal products within 12 months prior to&#xD;
             C1D1&#xD;
&#xD;
          -  Known or suspected hypersensitivity to IDE397/excipients or components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IDEAYA Clinical Trials</last_name>
    <phone>+1 650 534 3616</phone>
    <email>IDEAYAClinicalTrials@ideayabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Castaneda</last_name>
      <phone>480-323-7827</phone>
      <email>yvcastaneda@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>New Patient Services</last_name>
      <phone>800-826-4673</phone>
      <email>sthiagarajan@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne LaFary</last_name>
      <email>ylafary@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carvajal, MD</last_name>
      <phone>646-317-6330</phone>
      <email>rdc2150@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Seunath</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>32089</phone_ext>
      <email>Christina-Seunath@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>askSARAH</last_name>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon, MD</last_name>
      <phone>713-792-5603</phone>
      <email>JRodon@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Next Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Deleon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAT2A</keyword>
  <keyword>9p21</keyword>
  <keyword>CDKN2A</keyword>
  <keyword>MTAP</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>PRMT5</keyword>
  <keyword>SAM</keyword>
  <keyword>Synthetic Lethality</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>MTAP deletion</keyword>
  <keyword>CDKN2A deletion</keyword>
  <keyword>MAT2A Inhibitor</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Pancreatic or Pancreas Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Renal Cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

